News - Momenta Pharmaceuticals

Filter

Current filters:

Momenta Pharmaceuticals

Popular Filters

Court ruling favors Mylan in Copaxone patent dispute

17-07-2013

A US court has dismissed claims that US generic drugmaker Mylan (Nasdaq: MYL) infringed four patents…

CopaxoneGenericsMomenta PharmaceuticalsMylan LaboratoriesNatco PharmaNeurologicalNorth AmericaPatentsSandozTeva Pharmaceutical Industries

Future for biosimilars hugely promising, Momenta CEO tells GPhA meeting

26-02-2012

Craig Wheeler, chief executive of Momenta Pharmaceuticals (Nasdaq: MNTA) discussed the promise and prospects…

BiotechnologyGenericsMarkets & MarketingMomenta PharmaceuticalsResearch

Watson settles over Exalgo; gets favorable news on enoxaparin

29-01-2012

US generic drugmaker Watson Pharmaceuticals (NYSE: WPI) says that its subsidiary, Watson Laboratories,…

Cardio-vascularEnoxaparin Sodium InjectionExalgoGenericsLegalLovenoxMallinckrodtMomenta PharmaceuticalsNeurologicalNorth AmericaSanofiWatson Pharmaceuticals

Baxter taps Momenta expertise on biosimilars

28-12-2011

In another move to capitalize on the anticipated flood of biosimilars coming to the market, as blockbuster…

Baxter InternationalBiotechnologyGenericsLicensingMomenta PharmaceuticalsResearch

Teva prevails in Copaxone law suit with Mylan/Natco and Sandoz/Momenta

30-08-2011

Israel-headquartered Teva Pharmaceutical Industries (Nasdaq: TEVA) says that the US District Court for…

CopaxoneGenericsLegalMomenta PharmaceuticalsMylan LaboratoriesNatco PharmaNeurologicalNorth AmericaPatentsPharmaceuticalSandozTeva Pharmaceutical Industries

Company Spotlight

Fibrotech

Fibrotech

Back to top